ABUS - アルブ―タス・バイオファ―マ (Arbutus Biopharma Corporation) アルブ―タス・バイオファ―マ

 ABUSのチャート


 ABUSの企業情報

symbol ABUS
会社名 Arbutus Biopharma Corp (アルブ―タス・バイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering developing and commercializing a cure for patients suffering from chronic hepatitis B infection a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development which has enabled several clinical trials and has been administered to hundreds of human subjects.   アルブ―タス・バイオファ―マはカナダのバイオ医薬品企業。主に先進リボ核酸(RNA)干渉(RNAi)治療薬の研究開発に取り組み、製薬企業パ―トナ―に脂質ナノ粒子送達技術を提供する。慢性B型肝炎感染の患者に特化し、B型肝炎ウイルス(HBV)による肝臓疾患に対する治療法の発見、開発、商業化に従事する。本社はブリティッシュコロンビア州。   
本社所在地 100-8900 Glenlyon Parkway Burnaby British Columbia V5J 5J8 CAN
代表者氏名
代表者役職名
電話番号 +1 604-419-3200
設立年月日 38626
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 130人
url www.arbutusbio.com
nasdaq_url https://www.nasdaq.com/symbol/abus
adr_tso
EBITDA EBITDA(百万ドル) -66.20400
終値(lastsale) 9.11
時価総額(marketcap) 504733154.78
時価総額 時価総額(百万ドル) 332.42580
売上高 売上高(百万ドル) 12.10600
企業価値(EV) 企業価値(EV)(百万ドル) 298.47880
当期純利益 当期純利益(百万ドル) -84.55700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Arbutus Biopharma Corp revenues increased from $1.3M to $2.7M. Net loss applicable to common stockholders decreased 48% to $19.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Gain on investment increase from $0K to $24.9M (income).

 ABUSのテクニカル分析


 ABUSのニュース

   Global RNAi Therapeutics Market Opportunities & Challenges, Threat and Affecting Factors 2020-2027||Rexahn Pharmaceuticals, Inc., Silence Therapeutics, Arbutus Biopharma, Benitec Biopharma  2021/01/15 15:22:54 OpenPR
Data Bridge Market research released a new market study on RNAi therapeutics with 100+ market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis In RNAi therapeutics research report also directs the
   Michael J. Mcelhaugh Sells 40,000 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) Stock  2020/12/18 12:28:45 Watchlist News
Arbutus Biopharma Co. (NASDAQ:ABUS) insider Michael J. Mcelhaugh sold 40,000 shares of Arbutus Biopharma stock in a transaction that occurred on Monday, December 14th. The shares were sold at an average price of $5.00, for a total transaction of $200,000.00. Following the transaction, the insider now directly owns 1,337,457 shares in the company, valued at […]
   Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?  2020/12/17 14:31:00 PR Newswire
NEW YORK, Dec. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Thinking about buying stock in Hexo Corp, Electrameccanica Vehicles, BlackBerry, Arbutus Biopharma, or Virgin Galactic?  2020/12/01 14:31:00 PR Newswire
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HEXO, SOLO, BB, ABUS, and SPCE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Hepatitis B Infection Market 2020: Industry Analysis and Forecast : Top Key Players Apotex Inc, Accord Healthcare, Arbutus Biopharma, Aurobindo Pharma, Arrowhead Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc  2020/11/25 10:38:02 OpenPR
Data Bridge Market Research has recently added a concise research on the Hepatitis B infection Market to depict valuable insights related to significant market trends driving the industry. Hepatitis B infection Market report suggests that industry is anticipated to witness
   Michael J. Mcelhaugh Sells 40,000 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) Stock  2020/12/18 12:28:45 Watchlist News
Arbutus Biopharma Co. (NASDAQ:ABUS) insider Michael J. Mcelhaugh sold 40,000 shares of Arbutus Biopharma stock in a transaction that occurred on Monday, December 14th. The shares were sold at an average price of $5.00, for a total transaction of $200,000.00. Following the transaction, the insider now directly owns 1,337,457 shares in the company, valued at […]
   Thinking about buying stock in MacroGenics, Arbutus Biopharma, Riot Blockchain, Aclaris Therapeutics, or Myovant Sciences?  2020/12/17 14:31:00 PR Newswire
NEW YORK, Dec. 17, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MGNX, ABUS, RIOT, ACRS, and MYOV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Thinking about buying stock in Hexo Corp, Electrameccanica Vehicles, BlackBerry, Arbutus Biopharma, or Virgin Galactic?  2020/12/01 14:31:00 PR Newswire
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HEXO, SOLO, BB, ABUS, and SPCE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Hepatitis B Infection Market 2020: Industry Analysis and Forecast : Top Key Players Apotex Inc, Accord Healthcare, Arbutus Biopharma, Aurobindo Pharma, Arrowhead Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc  2020/11/25 10:38:02 OpenPR
Data Bridge Market Research has recently added a concise research on the Hepatitis B infection Market to depict valuable insights related to significant market trends driving the industry. Hepatitis B infection Market report suggests that industry is anticipated to witness
   Thinking about buying stock in Marathon Oil, Norwegian Cruise Line, Arbutus Biopharma, Ford Motor, or Spirit Airlines?  2020/11/16 14:31:00 PR Newswire
NEW YORK, Nov. 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRO, NCLH, ABUS, F, and SAVE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   Why Arbutus (ABUS) Stock Might be a Great Pick  2020/05/15 15:04:00 Zacks Investment Research
Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Moving Average Crossover Alert: Arbutus Biopharma  2020/05/11 15:19:00 Zacks Investment Research
Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
   Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates  2020/03/05 13:55:02 Zacks Investment Research
Arbutus (ABUS) delivered earnings and revenue surprises of 2.70% and 10.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
   Arbutus Biopharma misses on revenue  2020/03/05 12:32:40 Seeking Alpha
Arbutus Biopharma (NASDAQ:ABUS): FY GAAP EPS of -$2.89. Revenue of $6.01M (+1.0% Y/Y) misses by $0.62M. Press Release

 関連キーワード  (医薬品 米国株 アルブ―タス・バイオファ―マ ABUS Arbutus Biopharma Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)